You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 18, 2025

Bulk Pharmaceutical API Sources for SUFENTA PRESERVATIVE FREE


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for SUFENTA PRESERVATIVE FREE

Vendor Vendor Homepage Vendor Sku API Url
AbaChemScene ⤷  Get Started Free CS-3051 ⤷  Get Started Free
MedChemexpress MCE ⤷  Get Started Free HY-13754A ⤷  Get Started Free
AKos Consulting & Solutions ⤷  Get Started Free AKOS027325565 ⤷  Get Started Free
Sigma-Aldrich ⤷  Get Started Free S-008_CERILLIAN ⤷  Get Started Free
LGC Standards ⤷  Get Started Free LGCAMP1362.00-02 ⤷  Get Started Free
LGC Standards ⤷  Get Started Free LGCFOR1362.00 ⤷  Get Started Free
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for SUFENTA PRESERVATIVE FREE

Last updated: July 30, 2025


Introduction

Sufenta Preservative-Free, a potent opioid analgesic, is an essential medication in anesthesia and pain management. The active pharmaceutical ingredient (API), sufentanil, demands rigorous quality standards, particularly when produced without preservatives, to ensure safety and efficacy. Globally, established suppliers provide high-grade sufentanil APIs, adhering to stringent regulatory requirements. This analysis outlines the leading sources of sufentanil API suitable for preservative-free formulations, examining manufacturing capabilities, regulatory compliance, and market positioning.


Overview of Sufentanil API in Pharmaceutical Manufacturing

Sufentanil is a synthetic opioid analgesic synthesized through complex chemical processes involving multiple steps of organic synthesis, typically starting from precursor compounds like etomidate derivatives (although proprietary methods vary). The API’s purity, stability, and consistency are critical, especially for preservative-free products, to minimize contamination risk and ensure patient safety.

The demand for preservative-free sufentanil aligns with increased preferences for preservative-free formulations in clinical settings, emphasizing the importance of sourcing APIs that meet high purity standards, are manufactured under Good Manufacturing Practices (GMP), and possess comprehensive regulatory approvals.


Key Global API Suppliers for Sufentanil

1. Hikma Pharmaceuticals

Overview:
Hikma is a leading global manufacturer of generic pharmaceuticals, including opioid APIs like sufentanil. Its API manufacturing facilities are GMP-certified and adhere to international standards, supporting both branded and generic injectable drugs.

Capabilities:

  • Production of high-purity sufentanil API for injectables.
  • Extensive quality assurance, close regulatory scrutiny, and multiple certifications (FDA, EMA, PMDA).
  • Focus on preservative-free formulations, with dedicated manufacturing lines reducing contamination risks.

Market Presence:
Hikma supplies sufentanil API primarily to North America, Europe, and select Asian markets.


2. WuXi AppTec

Overview:
WuXi AppTec is a global Contract Research, Development, and Manufacturing Organization (CRDMO), known for integrated API production and custom synthesis services for complex molecules like sufentanil.

Capabilities:

  • Advanced synthetic routes enabling high purity (<99.9%) sufentanil API production.
  • Expertise in sterile, preservative-free APIs for injectable applications.
  • Proven compliance with GMP, ISO, and other regulatory standards.

Market Presence:
Serves pharmaceutical and biotech companies worldwide, with strategic manufacturing facilities in China, the US, and Europe.


3. Chinese Pharmaceutical API Producers

Overview:
China hosts a significant network of API manufacturers capable of producing sufentanil at high quality and competitive pricing. Several are certified under GMP and possess exporting licenses conforming to international standards.

Top Players:

  • North China Pharmaceutical Group Corp. (NCPC):
    Known for its robust API manufacturing capacity, including opioids such as sufentanil, with export to Europe and North America.

  • Zhejiang Hisun Pharmaceutical Co., Ltd.:
    Offers sufentanil APIs suitable for preservative-free injectable formulations, with comprehensive GMP certifications.

Capacity and Quality:
While these manufacturers often serve contract manufacturing needs, some have expanded to produce APIs for direct pharmaceutical use, under rigorous quality controls.


4. Indivior and Other Specialist API Suppliers

While Indivior primarily markets sufentanil products, it maintains strategic partnerships with API producers capable of supplying preservative-free sufentanil. These partners typically have established GMP facilities and global distribution channels.


Regulatory and Quality Considerations

For preservative-free sufentanil API, the critical factors include:

  • GMP Certification:
    Ensuring consistent manufacturing quality and product safety.

  • Free from Contaminants:
    Low levels of residual solvents, heavy metals, and endotoxins, especially pertinent for injectable APIs.

  • Regulatory Approvals:
    APIs sourced from suppliers with validations aligned with FDA, EMA, and other regulatory agency requirements to facilitate registration and market approval in various jurisdictions.

  • Traceability and Documentation:
    Supply chain transparency and comprehensive documentation, including batch records, are vital for quality assurance.


Emerging and Niche API Suppliers

Niche suppliers in India and Southeast Asia are increasingly capable of manufacturing sufentanil API, often certified under international standards. Their cost advantages, combined with ongoing investments in quality systems, make them attractive options, especially for markets with cost-sensitive demands.


Market Trends and Future Outlook

The global API market for sufentanil is consolidating, with fewer high-quality producers dominating. Increasing regulatory scrutiny favors suppliers with proven compliance records. Developments in synthetic chemistry and continuous manufacturing are expected to improve API purity and supply reliability.

The surge in demand for preservative-free opioids underscores the need for reliable, high-quality API sources. As new formulations emerge, pharmaceutical companies will prioritize suppliers demonstrating robust quality management, scalable capacity, and regulatory acceptance.


Conclusion

Sourcing sufentanil API suitable for preservative-free formulations requires a focus on quality, compliance, and supply stability. Leading suppliers such as Hikma Pharmaceuticals, WuXi AppTec, and key Chinese manufacturers offer high-purity, GMP-certified APIs tailored for injectable applications. Ongoing industry developments and stringent regulatory landscapes emphasize the importance of meticulous supplier validation and quality assurance practices.


Key Takeaways

  • The highest-quality sufentanil APIs come from established global manufacturers with GMP certification and regulatory approvals.
  • Preservative-free formulations demand APIs with ultra-high purity standards to mitigate contamination risks.
  • Regional manufacturing hubs, notably China and India, are expanding their quality capabilities, providing cost-effective options.
  • Companies should prioritize supply chain transparency, comprehensive documentation, and validation data during sourcing.
  • Continuous monitoring of regulatory changes and market trends is essential for securing reliable API sources in the evolving pharmaceutical landscape.

FAQs

Q1: What features distinguish sufentanil API suitable for preservative-free formulations?
A1: High purity (>99.9%), low residual solvents, endotoxin-free, and manufactured under GMP standards are essential to minimize contamination risk in preservative-free injectable products.

Q2: How can I verify the regulatory compliance of an API supplier?
A2: Confirm GMP certification, review audit reports, check for independent quality certifications (FDA, EMA, ISO), and request detailed documentation including batch release data.

Q3: Are Chinese API manufacturers reliable sources for sufentanil?
A3: Many have achieved GMP certification and meet international quality standards. Due diligence, including site audits and validation of certifications, is recommended before procurement.

Q4: What is the typical lead time for sourcing sufentanil API from established suppliers?
A4: Lead times vary from 8 to 24 weeks depending on order size, supplier location, and regulatory clearance processes.

Q5: How does the choice of API supplier impact the final preservative-free sufentanil product?
A5: The API quality directly influences product safety, stability, and efficacy; thus, selecting a reputable, compliant supplier ensures product integrity essential for preservative-free formulations.


References

  1. [1] Hikma Pharmaceuticals – Product Portfolio and GMP certifications.
  2. [2] WuXi AppTec – CMC capabilities and quality certifications.
  3. [3] Chinese API market reports – Industry analysis on manufacturing capacity and quality standards.
  4. [4] Good Manufacturing Practice (GMP) guidelines – WHO, FDA, EMA.
  5. [5] Industry reports on opioid API supply chain and market trends.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.